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ABSTRACT
Activin proteins are members of the transforming growth factor-β family. Activin A is involved in several 
biological responses including wound repair, cell death, proliferation and differentiation of many cell 
types. Biologically active activins consist of homodimers or heterodimers of two beta (β) subunits that 
are linked together by a single covalent disulphide bond. The subunits in humans are βA, βB, βC and 
βE. As an example, a combination of two βA subunits will produce a unit of activin A. These proteins 
are found in most cells of body such as macrophage and activated circulating monocytes. Their role 
in inflammation can be categorised into two types, either pro- or anti-inflammatory agents, depending 
on the cell type and phase. Activin signals are kept in balance by antagonist follistatin (Fst), which is a 
glycoprotein expressed in tissues and encoded by the follistatin gene in humans. 
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INTRODUCTION
Activin A is a multifunctional growth factor 
that is a functionally and structurally different 
member of the transforming growth factor-
beta (TGF-β) superfamily of proteins (Chang, 
Brown & Matzuk, 2002; Griselda, Anayansi, 
& Iván, 2012). Precursor proteins are the 
forms of activin produced after cleavage 
from bioactive ligands. They were given the 
name activin after the first identification as 
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activators of follicle-stimulating hormone (FSH) secreted from the pituitary gland (Ling et al., 
1986). These proteins also play an important role in regulating various biological functions 
in a many types of tissues and cells which include apoptosis, wound repair, differentiation of 
cells, survival of neural cell and inflammation (Yndestad et al., 2004).
Activins are involved in inducing mesodermal tissue differentiation in embryonic Xenopus 
explants (Griselda et al., 2012). Given their ability to accumulate and stimulate haemoglobin 
differentiation in erythroleukemia cell lines in vitro, these proteins were discovered through 
isolation from a monocytic leukaemic cell line derived from human bone marrow. The very 
first name given to activins was erythroid differentiating factor (EDF). Description of activin 
and its ligand as survival factors for nerve cells was the result of a search for nerve growth 
factors. Activin A was able to support the survival of the central nervous system (CNS) 
neurons in culture, as well as to protect neuronal injury from neurotoxicity due to its role as a 
neurotrophic and neuroprotective factor (Woodruff, 2000). Moreover, activin A affects liver 
homeostasis and may stimulate hepatocyte cell death (Woodruff, 1998). It is produced and 
secreted quickly into the bloodstream from the endothelium of the vascular system and other 
tissues during inflammation. Mediators such as nitric oxide and pro-inflammatory cytokines, 
as well as leucocyte activation, play a crucial role in numerous aspects of the inflammatory 
response. As seen in patients with either acute or chronic inflammation (e.g., septicaemia and 
inflammatory bowel disease), the concentrations of activin A were observed to have increased 
in the serum and tissues (Hubner, Brauchle, Gregor & Werner, 1997; Michel, Ebert, Phillips 
& Nau, 2003a).
Bioactive activins comprise either homodimers or heterodimers of two beta (β) subunits, 
with four distinct subunits of activin identified to date as being involved in the development 
of these proteins. These subunits in humans are βA, βB, βC and βE, which are able to produce 
activin A (βA/βA), activin B (βB/βB) and activin AB (βA/βB). Activin A homodimer is 
produced by merging two subunits of βA. This homodimer is produced by the creation of 
either an intermolecular disulphide bond or a covalently dimerised bond between the 6th (of 
the nine) conserved cysteines in the established proteins. The entire nine cysteines, excluding 
the 6th, are implicated in the production of a cysteine knot by means of disulphide bonds within 
the molecule. The disulphide bonds are typical for members of the TGF-α family and are 
fundamental for their effects on living tissues (Griselda et al., 2012; Kreidl, Oztürk, Metzner, 
Berger & Grusch, 2009).
SOURCE OF ACTIVIN A
Activin A is synthesised and secreted in almost every cell type and tissue. For the action of an 
autocrine or paracrine mechanism to be carried out, the tissues must be equipped with many 
receptors of activin A. Tissue macrophages and activated circulating monocytes can synthesise 
and release activin A after stimulation by inflammatory stimuli. A large amount of activin A is 
secreted by bone marrow stromal cells in response to inflammatory mediators (Phillips, Jones, 
Scheerlinck, Hedger & de Kretser, 2001; Welt, Sidis, Keutmann & Schneyer, 2002). Activin A 
is released from bone marrow stromal cells after stimulation of the vascular endothelium by 
monocytes and bone marrow stromal fibroblasts once T-cells have interacted with cytokine. 
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Therefore, Bone marrow is another effective source of activin A and also a source of activin 
A during inflammation (Wu, Chen, Winnall, Phillips & Hedger, 2013). Additionally, strong 
stimulation by lipopolysaccharide (LPS), interleukin (IL)-1β or IL-6 also leads to the production 
of activin A by macrophages, monocytes and endothelial cells. In systemic inflammation, 
endothelial cells may be an essential depot of activin A activity (Phillips, Jones, Clarke, 
Scheerlinck & de Kretser, 2005; Phillips et al., 2001). Furthermore, secretion of activin A 
can be enhanced by mutual action between monocytes and activated T-cells via CD-40 (Abe, 
Shintani, Eto, Harada, Kosaka & Matsumoto, 2002). Moreover, mast cells and neutrophils 
are other potential sources of activin A during inflammation, while activin A can be produced 
after treatment with interferon (IFN)-γ and CD40L, or LPS when dendritic cells interact with 
activated T-cells (Phillips et al., 2005; de Kretser, O’Hehir, Hardy & Hedger, 2011).
ACTIVIN A SUBUNIT
Fig.1:  A subunit of activin A (Adapted from Activin-A Binds Follistatin and Type II Receptors through 
Overlapping Binding Sites: Generation of Mutants with Isolated Binding Activities by Harrison, C. A. 
& Chan, K. L., 2008, Endocrinology, 147(6), 2744-2753).
The binding sites for type II receptor are located at finger 1 (Phe17, Ile30, AL31, Pro32, His36) and 
finger 2 (Arg87, Pro88, Ser90, Leu92, Tyr94, Ile100, Lys102, Glu111) of activin A. Follisatin can bind to 
contiguous site on activin A. The first is the convex outer side of activin β strand (Ile30, AL31, 
Pro32, Leu92, Tyr9, Ile100 and Lys102) and in β strand fingertip (Asp32 – Asn99). The second is the 
binding site of type I receptor that is formed by the concave activin β strand of one subunit 
(Trp25, Trp28, Met91, Tyr93 and Ile105) and helical wrist region on the other β subunit (His47, Ile48, 
Gly50, Thr51, Ser52, Phe58, Thr61 and His65) (Harrison, Chan & Robertson, 2006).
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ACTIVIN A SIGNALING PATHWAY
Since activins are members of the TGF-β family of signaling molecules, mature activins are 
believed to signal through single-pass transmembrane serine-threonine kinase receptors type I 
and type II, both of which are crucial for activin-mediated biological activities. The cytoplasmic 
region of both type I and type II receptors is the region where the serine-threonine activity 
takes place, which also serves as the docking stations. The signalling pathway started by the 
attachment of activin A to dimers of the activin type-II receptors ActR-II, which are also known 
as ACVR2 or ActR-IIB (ACVR2B).
Consequently, dimers of the activin type I receptor (activin receptor-like kinase [ALK] 4) 
are recruited and phosphorylated in their type-II serine-threonine kinase domain. The primary 
residues within a glycine- and serine-rich (GS) domain of the type I receptor are phosphorylated 
by the assembled active type II receptor, as a consequence of the formation of the heteromeric 
ligand-receptor complex, which brings together the cytoplasmic region of the two types of 
receptors. The activation of intracellular protein Smads is the result of the activation of activin 
type I receptors. It was found that the mutually dependent characteristic of activin type I and 
type II receptors is due to the need of activin type I receptors to bind their ligand to activin 
type II receptors, whilst the association of type II receptors to type I receptors is important 
to signal the nucleus (Bilezikjian & Vale, 2011). Although the binding of type II receptors to 
ligands can take place without the presence of type I receptors, they still need the latter to 
signal and function well.
Receptors of activin are regularly internalized immediately after the binding of ligand. 
Immediately after receptor activation, phosphorylation of receptor-regulated Smad (R-Smad) 
proteins by the activin type I receptors takes place after their recruitment to the receptor 
complex. Molecular complexes are formed after the common mediator Smad 4 approaches 
the recruited and phosphorylated R-Smads (Smads 2 & 3). Modulation of gene expression 
is initiated by direct binding to DNA or association with other transcription factors by the 
molecular complexes that come together with cofactors. The phosphatidylinositol-3′-phosphate-
binding protein, known as Smad anchor for activation of the receptor (SARA), is responsible for 
phosphorylation of Smads 2 and 3. Smads 2 and 3 are bound together to the receptor complex 
with the aid of SARA. R-Smads and SARA are cleaved from the receptor complex once 
R-Smad proteins are phosphorylated. Gene expression is initiated following the translocation 
of phosphorylated R-Smads after the recruitment of the cytoplasmic common mediator Smad, 
the co-Smad 4 (Schmierer, Schuster, Shkumatava & Kuchler, 2003; Kreidl et al., 2009; Griselda 
et al., 2012; Cárcamo et al., 1994; Wieser, Attisano, Wrana & Massagué, 1993).
The Smad proteins are generally divided into two subcategories: R-Smads (receptor-
activated) or co-Smad (not receptor-activated) (Bilezikjian & Vale, 2011). Smad proteins have 
an N-terminal against decapentaplegic homology domain 1 (MH1) and a C-terminal against 
decapentaplegic homology 2 (MH2) linked by a proline-rich region. Binding of DNA to the 
CAGA sequence, as well as to some GC-rich sequences, is mediated by the MH1 domain, which 
contains a nuclear localisation signal. Transcription activation only happens when the MH2 
domain is fused to the Gal4 DNA-binding domain. For MH2-specific association with the L45 
loop of activin type I receptors, as well as in the homo- or hetero-oligomerisation of Smads, 
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the presence of L3 loop containing in MH2 is important (Bilezikjian & Vale, 2011; Ten Dijke, 
Miyazono & Heldin, 2000). The conserved C-terminal SSXS motif in R-Smads is recognized 
by the tail of activin type I receptors in the cytoplasmic region. The association between Smad 
4 and R-Smad is initiated after the cleavage of R-Smad from activin type I receptors due to 
the phosphorylation of the C-terminal SSXS. Consequently, this initiates translocation of the 
heteromeric Smad complex to the nucleus (Attisano & Wrana, 2000; Bilezikjian & Vale, 2011).
Fig.3: A schematic diagram of the Smad protein with an N-terminal Mad Homology 1 (MH1) and a 
C-terminal Mad Homology 2 (MH2) domain linked by a proline-rich region.
Smad 3 recognises the two inverted repeats of GTCT on DNA. However, the single copy 
of this core sequence only bound by the MH1 of Smad 3. The MH1 of Smad 2 cannot bind to 
DNA by itself. In addition, the repeat sequence of GNCN in the promoter are not sufficient for 
binding to Smad-dependent targeting of specific genes, but it is enough for Smad-DNA binding. 
Fig.2: Activin/ Smad signalling pathway
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The most comprehensively characterised DNA-binding partners of the Smad proteins are the 
forkhead activin signal transducer (FAST) family of DNA-binding proteins. Furthermore, the 
family has been identified in humans and mice as well. The TGF-β activin-responsive region 
of promoters acts mutually with FAST in order to activate gene transcription downstream of 
activin signaling (Attisano & Wrana, 2000).
ACTIVIN AS A MEDIATOR IN INFLAMMATION: ACUTE AND CHRONIC
At the site of injury, inflammation quickly develops as the consequence of the secretion of 
inflammatory cytokines (IL-1, IL-6 and tumour necrosis factor-alpha (TNF-α)] from cells such 
as macrophages and stromal cells. In succession, acute phase response (APR) is stimulated 
after these cytokines act at systemic sites such as the liver to trigger febrile responses and gene 
expression (de Kretser, Hedger & Phillips, 1999). Sites of the injury are protected by innate 
response by APR to prevent host from continuous tissue damage. Some physical changes are 
protected by innate response, which in turn, suppresses actions of serum acute phase proteins 
and cytokines (Steel & Whitehead, 1994). Damage of lung during LPS-induced inflammation 
occurs after neutrophils translocate from bone marrow. Activin A is secreted during inflammation 
by neutrophils following direct stimulation by TNF-α; serum TNF-α is reduced if activin A 
is blocked. After 4 and 5 hours of LPS introduction, serum activin A level is greatly elevated 
(Wu et al., 2013; de Kretser et al., 1999). The activin A released during acute inflammation 
is very early and biphasic. Its release during early acute inflammation is rapid and therefore 
from pre-stored materials. Its secretion during the later phases of inflammatory responses is 
from newly synthesised inactive material hours after stimulation such as by LPS. The cells that 
are responsible for the production of activin A at the later stage are monocytes, macrophages, 
dendritic cells and endothelial cells. Neutrophils and epithelial cells are responsible for activin 
A secretion such as those from the stomach and lungs (Philips et al., 2009).
Upregulation of activin A expression at the sites of injury is either as protein or mRNA in 
synovial fluid or in chronic inflammatory bowel disease (IBD) in patients with inflammatory 
arthropathy (de Kretser et al., 1999). In chronic inflammation, comparing patients with gout 
and rheumatoid arthritis with those with non-inflammatory osteoarthritis, activin A levels were 
elevated in synovial fluid, as well as expression of activin βA in synovial membranes. Activin 
A has been implicated in IBD. The ulcerative colitis or Crohn’s disease from IBD patients, 
inflamed mucosal and sub-mucosal tissues in the intestinal wall were observed, together with 
high IL-1β and activin βA subunit mRNA levels. In normal tissues, expression of IL-1β was 
low (Philips et al., 2009). This same group of patients also displayed very high level of plasma 
activin A level and βA mRNA in the intestinal wall. Moreover, in areas where IL-1β mRNA 
was highly expressed, activin βA subunit mRNA was found in the mucosa and sub-mucosa of 
tissues at sites of inflammation, whereas low levels of expression were found in healthy tissues; 
for example, the activin A-stimulated production of IL-6 and IL-8 in amniotic membranes. The 
action of activin A is believed to have two phases; inhibitory as the activin A concentration is 
high and vice versa (Wu et al., 2013).
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ACTIVIN A: A PRO-INFLAMMATORY AGENT
A pro-inflammatory role for activin A has been observed in diverse cell types (Jones, de Kretser, 
Patella, & Phillips, 2004). The role of activin A as a pro-inflammatory mediator is proved by 
the upregulation of activin expression by pro-inflammatory cytokines (granulocyte monocyte 
colony-stimulating factor (GM-CSF) and interferon γ) and/or LPS, as well as down regulation 
by glucocorticoids. The role of activin A during pro-inflammatory activities was confirmed by 
its pro-migratory on monocytes. Additionally, metalloproteinase expression can be induced 
by activin A in macrophages during the inflammatory response. Migration and infiltration 
by macrophages through the basement membrane during inflammation are also triggered by 
activin A. Taking malarial infection as an example, it is important that cells are first activated 
by parasite-specific molecules to initiate immune responses against the infection. This is then 
followed by the activation of mitogen-activated protein kinase (MAPK) and nuclear factor 
(NFκB) signalling pathways, resulting in expression of cytokine genes (El-Gendi et al., 2010; 
Zhu, Krishnegowda, Li & Gowda, 2010).
In malarial infection, macrophages phagocytose the invading parasites. During this process, 
the release of pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1β can be stimulated 
by activin A (Rapeah, Dhaniah, Nurul & Norazmi, 2010; Phillips et al., 2005). In bone 
marrow-derived macrophages, TNF-α and IL-1β are also produced following the stimulation 
of activin A. Moreover, activin A increases the expression of pro-inflammatory mediators such 
as prostanoids, prostaglandin and thromboxane, cyclo-oxygenase 2 (COX-2), and inducible 
nitric oxide synthase (iNOS) (Jones et al., 2004; Nusing & Barsig, 1999). The pro-inflammatory 
effects of activin A can also be seen in LPS-induced inflammation process in sheep. This 
involves the pro-inflammatory cytokines TNF-α and IL-6, which are secreted following the 
release of activin A. Activin A has also been implicated in stimulating the production of IL-6 and 
IL-8 in amniotic membranes, where its role as a pro- or anti-inflammatory agent depends on its 
concentration. When the activin concentration is low, it acts as a pro-inflammatory factor, and 
when it is high, an anti-inflammatory agent (Jones et al., 2004). Additionally, IκB degradation, 
nuclear translocation of NFκB and phosphorylation of Extracellular signal-regulated kinases 
1/2 (ERK 1/2) and p38 MAPK lead to the production of TNF-α, IL-1β and IL-6 by activin A 
(Phillips, de Kretser & Hedger, 2009).
ACTIVIN A: AN ANTI-INFLAMMATORY AGENT
Activin A has been well documented an anti-inflammatory agent, with evidence that activin A 
can limit the secretion and actions of IL-1β and IL-6 (Phillips et al., 2001). A study on monocytic 
cultures uncovered the ability of activin A to keep down the production of IL-1β by inhibiting 
the alteration of the IL-1β precursor into its secreted biologically active form, most likely by 
blocking caspase-1 (Philips et al., 2009; Phillips et al., 2011). In LPS-stimulated macrophages, 
activin A can suppress the secretion and expression of IL-1β and IL-10 (de Kretser et al., 2011; 
Wang et al., 2008). During the early stage of inflammation induced by macrophage, the pro-
inflammatory effect of activin A is turned into anti-inflammatory at the later stage (de Kretser 
et al., 2011). During APRs, activin A is able to initiate anti-inflammatory effects at local site 
of infection or injury and to repress unnecessary inflammation at the pheripheral sites such as 
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liver (Smith et al., 2004). Moreover, theactivity of activin A in a hepatoma cell line (HepG2) 
can be inhibited by a secretion of acute phase inflammatory proteins mediated by IL-6 (Werner 
& Alzheimer, 2006). With the aid of activin A, the pancreatic islet cells and endothelial cells of 
humans are able to produce insulin and anti-inflammatory effects, as well as anti-oxidative and 
anti-inflammatory effects. In patients with coronary artery disease (CAD), anti-inflammatory 
effects on previously activated peripheral blood mononuclear cells are also displayed by activin 
A (Andersen et al., 2011). The anti-inflammatory effects of activin A are also proven, with 
antagonistic action on the secretion of IL-6 and IL-11 in myeloblasts (Sugama, Takenouchi, 
Kitani, Fujita & Hashimoto, 2007). During the early phase of cardiopulmonary bypass (CPB), 
the anti-inflammatory effects of activin A only occur after the production of pro-inflammatory 
cytokines such as TNF-α and IL-8 (Sablotzki et al., 1997).
ACTIVIN IN ORGAN SPECIFIC FUNCTIONS
In the brain, differentiation of cerebrocorticol neural progenitor cells (NPC) into neuronal 
phenotype is driven by activin A. In proliferating NPC, activin can induce discrete but 
significant rises in the proportion of neurons. The neurogenesis by activin is not due to its role 
as regulator but as an instructor on NPC. In addition, inhibition of activin can cause reduced 
neurogenesis and development of anxiety-related behavior (Rodríguez-Martínez, Molina-
Hernández & Velasco, 2012).
Activin A is upregulated in heart failure but treatment with anti-activin A antibody can 
restore growth hormone (GH) which improves heart function by normalizing GH level 
(Fukushima et al., 2011). Activin A has also been identified to play a role in healing after 
myocardial infarction, but a continuous increase in activin A levels can lead to myocardial 
remodelling and eventually heart failure (Yndestad et al., 2004). Recovery could be due to 
the presence of high serum activin levels that cause a reduction by upregulating expression of 
B-cell lymphoma 2 (Bcl-2) protein (Oshima et al., 2009).
Activin A has been proven to function as a negative regulator for liver growth. It can 
inhibit mitogen-induced DNA synthesis and induce apoptosis in cell lines of hepatoma and in 
hepatocytes in vivo as well as in vitro. Overproduction of activin A due to inhibin deficiency 
can cause hepatocyte destruction. Activin A remained at low levels at the first 12 hours of 
partial hepatectomy (PHX) and increased by three times higher at 168 hours, which suggests 
that it acts as regulator of liver regeneration. Furthermore, hepatocyte replication increased 
following the elevation of follistatin at 24-48 hours of post PHX (Rodgarkia-Dara et al., 2006).
In kidney, activin A is important as a negative regulator in the growth of ureter bud (UB) 
from Wolffian duct (WD) during the development of metanephric kidney. UB outgrowth is in 
response to glial-cell-derived neurotrophic growth factor (GDNF). Thus, ectopic bud formation 
can be controlled by inhibiting GDNF by activin A. Activin A is also involves in branching 
morphogenesis of UB by acting as negative regulator (Maeshima et al., 2004). Activin A in 
pancreas is crucial for glucose metabolism by stimulating differentiation of β cells to produce 
insulin, which allows insulin target cells to act efficiently in glucose uptake (Hashimoto & 
Funaba, 2011; Ueland et al., 2012).
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ROLE OF ACTIVIN IN DISEASES
During malaria parasite infection, pro-inflammatory cytokines like TNF-α and IFN-γ, and 
anti-inflammatory cytokine like IL-10 are produced to provide protection against the parasites. 
In malarial infection, activin A initiates the release of pro-inflammatory cytokines such as 
TNF-α, and IFN-γ and IL-10 production is activated upon enhancement of inflammation. 
These cytokines are important in protection against malaria parasites (Semitekolou et al., 
2009; Phillips et al., 2005; Gribi, Tanaka, Harper-Summers & Yu, 2005; Robinson et al., 2009).
Activin A has been identified to be involved in the pathogenesis of inflammation bowel 
disease (IBD), enhancing the migration instead of proliferation of intestinal epithelial cells, 
as well as stimulating inflammation during colitis (Huber et al., 1997; Zhang, Resta, Jung, 
Barrett & Sarvetnick, 2009). In patients with ulcerative colitis or Crohn’s disease, strong 
expression of the activin βA subunit was detected, but not in people with a healthy digestive 
tract. Moreover, the higher the expression of activin βA mRNA was, the more severe the degree 
of inflammation would be. Increased expression of activin A mRNA has been identified in 
highly inflamed tissues such as the mucosa and sub-mucosa of injured intestinal epithelium 
(Hubner et al., 1997). Furthermore, increased expression of type I and type II activin receptors 
has also been reported in patients with IBD but not in healthy people, indicating that activin 
signalling contributes to the enhanced receptor expression (Zhang et al., 2009).
In patients with asthma, increased concentration of activin A in bronchoalveolar lavage 
fluid is due to its secretion from cells lining the alveoli, which are epithelial cells and activated 
human lung mast cells (Philips et al., 2009; Werner & Alzheimer, 2006). Alveolar cells, 
endothelial cells and fibroblasts were found to respond to activin in inflamed lung tissues, which 
was supported by the strong ActR-IB expression in these cells. Mice deficient in mast cells 
shows lower secretion of activin A; therefore, mast cells are an important source of activin in 
the airway of mice with asthma. It is believed that mast cell-derived activin A could promote 
airway tissue remodelling, as activin A was found to enhance the proliferation of airway 
smooth muscle (ASM) cells in humans. The action is completed with paracrine signalling to 
enhance the proliferation of ASM cells. Activin increases the differentiation and migration of 
mast cell progenitors but inhibits growth. For that reason, activin A may regulate mast cells 
as the effector cell of the immune system, which could further contribute to the pathogenesis 
of asthma (Werner & Alzheimer, 2006).
CURRENT RESEARCH FINDINGS AND NEW TREND FOR ACTIVIN 
RESEARCH
Activin has been identified to be involved in the control of biological systems and wide 
interaction with other members of TGF-β superfamily, as well as other hormones/peptides. 
The motivation underlying the study by Makanji et al. (2011) is the apparent role of activin 
in promoting cachexia in patients with a variety of tumours and promoting development of 
gonadal tumours. However, the value of this study is much broader.
The non-specific interaction of activin and other TGF-β superfamily, together with 
regulation and signalling of other family members, makes the identification of specific action 
and the development of specific agonists and antagonists very challenging. In this study, genetic 
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manipulations (transgenic animals or in vitro small interfering RNA gene knockdown) are useful 
only with the aid of specific agonistic and antagonistic compounds for the peptide of interest. 
The system’s biology framework was used to create specific antagonist (activin propetide [AT 
propetide]) that inhibits activin A stimulation of FSH release. Specific domains for protein 
folding were determined by study on the molecular two- and three-dimensional structures of 
activin and TGF-β1 peptide so that the structure that binds and inhibits mature TGF-β1 can 
be created. The inhibition of activin action by chimeric peptide was achieved through the 
linking of C-terminal portion of activin with the N-terminal portion of TGF-β1. The specificity 
of AT propeptide was important in genetic manipulation. The AT propeptide allows insight 
into functions of activin and mechanisms of interaction with other TGF-β1 members such as 
inhibin. New therapies for cancer and other diseases could be developed from this chimeric 
propeptide. Hence, this study is valuable and may be rewarding upon the proper application 
of the 21st century systems biology thinking (Nielsen & Torday, 2011).
FOLLISTATIN: AN ANTAGONIST OF ACTIVIN A
The single-chain glycoprotein and structurally different follistatin was recognised as an 
extracellular antagonist of activin that could reduce its biological activities. The LPS- or IL-
1β dosed sheep has proven the involvement of follistatin during inflammation. Follistatin is 
a monomeric protein and is structurally different to the TGF-β superfamily of proteins. Most 
organs that express follistatin also express activin; consequencely, follistatin activities in nature 
likely to have an autocrine or paracrine characteristic. The bond between follistatin and activin 
is very strong, with Kd 50-680 pmol/L. In addition, the local diffusion of activin A from the 
site of action can be controlled by follistatin (Deli et al., 2008; Welt et al., 2002; Oshima et 
al., 2009). The bond between follistatin and activin is virtually irreversible; however, activin 
must be cleaved by proteolytic mechanism to reveal its endocrine signalling effects. Such a 
mechanism has been identified for the related bone marrow macrophage protein (BMP), in 
which bioactive BMP is released from chordin, its binding protein, by metalloproteinase (Welt 
et al., 2002).
A third of activin residues are buried at the binding sites of receptor as soon as one activin 
dimer binds to two follistatin molecules. Three distinct types of follistatins are produced 
through the protein processing and splicing of a single follistatin gene. They are proteins with 
288, 303 and 315 amino acids. Three homologous domains are contained in each of these 
three follistatins. In case of inhibition of activin, only two domains are involved in the binding 
process (Deli et al., 2008). The inhibitory action occurs only when the receptor binding site of 
activin A is obstructed by complex formation with follistatin (Kreidl et al., 2009). Follistatin 
has an important role in suppressing activin A, as it can reduce mortality rate by reducing the 
excessive production of activin A during inflammation (Wu et al., 2013; Jones et al., 2004). For 
example, over scarring as well as formation of granule and re-epithelisation on wounded skin 
is under the influence of a high concentration of activin A but healing quality can be restored 
with the aid of follistatin (Werner & Alzheimer, 2006). Furthermore, liver apoptosis induced 
by activin A can be inhibited with follstatin as well (Oshima et al., 2009).
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CONCLUSION
Activin A has been linked to inflammation, cells growth, tissue repair, metabolism and 
apoptosis. The focus of this review is on its role in inflammatory response. Its expression is 
significantly upregulated during acute and chronic inflammation. Activin can be involved in both 
pro- and anti-inflammatory responses depending on the cell type and stage of its expression. 
Inflammation has always been a major biological response related to activin, such as that in 
malaria infection, IBD and asthma. Besides, activin has different functions in organs, while in 
brain, it has a role in neurogenesis. It also improves heart failure and healing after myocardial 
infarction and acts as a regulator of liver regeneration after PHX in the liver, growth of UB from 
WD and branching of UB, and glucose metabolism in pancreas. Nonetheless, further studies 
are required to identify and understand the roles of activin in other pathological conditions.
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